Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus
about
Cardiovascular safety of anti-diabetic drugsStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewEmpagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.De novo expression of sodium-glucose cotransporter SGLT2 in Bowman's capsule coincides with replacement of parietal epithelial cell layer with proximal tubule-like epithelium.Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesSodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin.Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes MellitusSubstantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled StudySafe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Is it time to think about the sodium glucose co-transporter 2 sympathetically?Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.Crosstalk of Hyperglycemia and Dyslipidemia in Diabetic Kidney Disease.Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis
P2860
Q26741082-96A1FAEE-EDEE-4D7C-8688-668CE05881F5Q28069065-063405D7-32A4-4F2B-99CC-61B9CB70AB02Q28074843-6FCC9A1E-381C-4963-A3CC-AF519540FF3FQ28079134-BCE607D1-CCD6-459F-9599-A883DD76D7D1Q33837017-6A6A1B29-565D-45E8-A536-2C5251E48893Q33983846-B1505C56-A53D-49C2-AF47-CD1ADAF0EACFQ34201551-44F2E4AA-89C0-4485-A5BE-D4605C3C9283Q34503796-FBEBA60C-983D-4995-BA67-401E79972280Q35558413-1A5B38DE-37BC-4748-87AE-F1B240A92F34Q35780861-F762DBF5-8627-4EBC-B98F-97D35C6D0EAFQ35831426-2EDAFD0F-5798-4BC3-8827-86FCBB5652E3Q36169413-4679DC0E-DDE3-47D1-B6CC-1E39B01F0F14Q36804248-C6729727-E71A-483F-AE7D-C03F0DE87F08Q37080615-B6FFB048-CE6C-401F-B8C8-5954F40623D0Q37588847-CE2557E7-14B6-483D-9E4D-CB4D6E20268EQ38586588-89B2A244-3F5D-4FAB-A4D3-413752ADECEAQ38783203-B1B4DA8C-110D-4BB3-87FC-FF2C0E65D86EQ38906041-45C9D957-D393-49C5-9392-B94E44FC2662Q39006105-7FA8A613-3FD1-419C-8442-5C29E1280889Q39865389-0FE91E18-9C91-4FCE-B7BE-A4F3D32858F8Q47766606-9A151687-1E90-49B5-AAD8-A4B793A2EA19Q49982517-4F156261-3C52-48B7-A44D-E2112C439BE9Q53322628-DAAFA17B-4C55-4562-8684-C06EFE3D4EFAQ58797007-6F978D49-C35F-4BE1-BB21-FE6920068AF0
P2860
Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sodium Glucose Co-transporter ...... c Control in Diabetes Mellitus
@en
Sodium Glucose Co-transporter Type 2
@nl
type
label
Sodium Glucose Co-transporter ...... c Control in Diabetes Mellitus
@en
Sodium Glucose Co-transporter Type 2
@nl
prefLabel
Sodium Glucose Co-transporter ...... c Control in Diabetes Mellitus
@en
Sodium Glucose Co-transporter Type 2
@nl
P2860
P921
P1433
P1476
Sodium Glucose Co-transporter ...... c Control in Diabetes Mellitus
@en
P2093
Harold Bays
P2860
P2888
P304
P356
10.1007/S13300-013-0042-Y
P577
2013-10-19T00:00:00Z